SOURCE: MedinCell

MedinCell

August 09, 2011 04:49 ET

MedinCell Invites Data Review for Long-Acting, Controlled-Release Schizophrenia Treatments

MONTPELLIER, FRANCE and SAN DIEGO, CA--(Marketwire - Aug 9, 2011) - MedinCell, developer of the MedinGel™ biodegradable drug release platform, is pleased to invite potential pharmaceutical development partners to review data from their RisperMed pilot program.

"Schizophrenia is a tragic and severe condition with challenging dose and compliance issues. We've designed the RisperMed program to address clinical needs that are unmet by today's oral and injectable Risperidone products," said Dr. Stephane Lucchini, MedinCell's Business Development Manager. "RisperMed, if approved, will be the first once-quarterly, subcutaneous antipsychotic product available for the long-acting injectable antipsychotic market. Additionally, by using subcutaneous delivery to minimize administration discomfort, we believe RisperMed will improve treatment adherence -- which has been estimated to cost the US over $1.4 billion per year," Lucchini concluded.

Potential partners may request access to the RisperMed Data Room through MedinCell's web portal (http://www.medincell.com/news/rispermed), and will have until September 23, 2011 (4:00 pm EDT) to gauge the effectiveness of the MedinGel formulations and propose licensing terms. The repository includes an analysis of the schizophrenia treatment market space, in vitro and in vivo pharmacokinetic data from candidate Risperidone formulations, and histopathology comments regarding injection safety in animal models. MedinCell will also show release profile and cost of goods comparisons with the only existing long-acting injectable risperidone product, Risperdal® Consta®*, which achieved global sales of $1.5 billion in 2010.

"The MedinGel System uses a proprietary polymer matrix to form a semi-solid depot after subcutaneous injection," explained Dr. George Gaudriault, CSO for MedinCell. "This hydrogel-based depot protects drug molecules and can be fine tuned to control release rates. This frequently enables us to design multiple target durations for the same molecule for greater treatment flexibility," he added.

"By offering weekly, monthly and 3-month durations with low projected final formulation costs, the RisperMed product suite would be the first feasible schizophrenia treatment for emerging global markets," commented Dr. Anh Nguyen, Founder and CEO of MedinCell. "MedinCell's driving purpose is to design products that can effectively treat the broadest patient populations. We help partners overcome traditional pharmaceutical market barriers -- such as diverse economic conditions -- and look forward to bringing novel treatment options to schizophrenia patients across the globe," Nguyen added.

About MedinCell
Using proprietary polymer technology, MedinCell designs controlled-release formulations that form a biodegradable, biocompatible matrix after administration. This patent-pending MedinGel™ technology limits the initial release of drug molecules to reduce off-target effects and extend release duration. This also allows Medincell's formulations to use substantially reduced API amounts in sustained release formulations. MedinCell SA is headquartered in Montpellier, France, and recently launched formulation and R&D activities at its US subsidiary, MedinCell Corporation, in San Diego, California. Contact information for both facilities is available online: http://www.medincell.com/contact

*Risperdal® and Risperdal® Consta® are registered trademarks of Johnson & Johnson Corporation.

Contact Information

  • Press contact:
    Christopher Hoover
    MedinCell Corporation
    10451 Roselle St, Suite 200
    San Diego CA 92121 USA
    +1 (858) 216-4573 phone
    Email Contact